Literature DB >> 15716209

Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum.

Xin-Hua Zhang1, Annamaria Morelli, Michaela Luconi, Linda Vignozzi, Sandra Filippi, Mirca Marini, Gabriella Barbara Vannelli, Rosa Mancina, Gianni Forti, Mario Maggi.   

Abstract

OBJECTIVES: To investigate the effect of testosterone on PDE5 expression and PDE5 inhibitor tadalafil in vivo responsiveness in a rat model.
METHODS: PDE5 expression was localized by immunohistochemistry in the rat corpus cavernosum (CC) and quantified by both real-time RT-PCR and Western blot analysis in several tissues. In the in vivo study, control, castrated and testosterone (T) supplemented castrated rats were treated with acute or chronic oral tadalafil. Erectile function was evaluated by monitoring intracavernous pressure (ICP) following electro-stimulation (ES) of the cavernous nerve and intracavernous injection of NO donor, sodium nitroprusside (SNP).
RESULTS: Rat CC expressed the highest PDE5 mRNA level. PDE5 was specifically immunolocalized in endothelial and smooth muscle cells. Surgical castration induced a significant reduction of PDE5 gene and protein expression (p<0.05), and ES response at all stimulation frequencies (p<0.001). T supplementation completely restored PDE5 expression, erectile response to ES and responsiveness to PDE5 inhibitor. Both acute and chronic tadalafil treatment were ineffective in ameliorating the ES response in castrated rats. Injection of increasing concentrations of SNP in castrated rats resulted in a statistically significant increase in ICP/MAP ratio as that observed in intact rats. In addition, tadalafil did not amplify the SNP effect in castrated rats at all the doses tested (0.06-6 nmoles).
CONCLUSIONS: Our findings demonstrate that testosterone positively regulates PDE5 expression and in vivo responsiveness to PDE5 inhibitor, tadalafil, in the rat CC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15716209     DOI: 10.1016/j.eururo.2004.10.021

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  38 in total

Review 1.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

2.  Testosterone replacement in transgenic sickle cell mice controls priapic activity and upregulates PDE5 expression and eNOS activity in the penis.

Authors:  B Musicki; S Karakus; W Akakpo; F H Silva; J Liu; H Chen; B R Zirkin; A L Burnett
Journal:  Andrology       Date:  2017-11-16       Impact factor: 3.842

Review 3.  Translational Perspective on the Role of Testosterone in Sexual Function and Dysfunction.

Authors:  Carol A Podlasek; John Mulhall; Kelvin Davies; Christopher J Wingard; Johanna L Hannan; Trinity J Bivalacqua; Biljana Musicki; Mohit Khera; Nestor F González-Cadavid; Arthur L Burnett
Journal:  J Sex Med       Date:  2016-08       Impact factor: 3.802

Review 4.  The role of testosterone in erectile dysfunction.

Authors:  Giovanni Corona; Mario Maggi
Journal:  Nat Rev Urol       Date:  2009-12-08       Impact factor: 14.432

5.  Smooth muscle myosin expression, isoform composition, and functional activities in rat corpus cavernosum altered by the streptozotocin-induced type 1 diabetes.

Authors:  Xinhua Zhang; Nirmala D Kanika; Arnold Melman; Michael E DiSanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-09-13       Impact factor: 4.310

6.  Synergetic effect of testosterone and phophodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review.

Authors:  Naif Alhathal; Ahmed M Elshal; Serge Carrier
Journal:  Can Urol Assoc J       Date:  2012-08       Impact factor: 1.862

Review 7.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

Review 8.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

Review 9.  Which patients with sexual dysfunction are suitable for testosterone replacement therapy?

Authors:  A Morelli; G Corona; S Filippi; S Ambrosini; G Forti; L Vignozzi; M Maggi
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

Review 10.  Erectile dysfunction.

Authors:  Faysal A Yafi; Lawrence Jenkins; Maarten Albersen; Giovanni Corona; Andrea M Isidori; Shari Goldfarb; Mario Maggi; Christian J Nelson; Sharon Parish; Andrea Salonia; Ronny Tan; John P Mulhall; Wayne J G Hellstrom
Journal:  Nat Rev Dis Primers       Date:  2016-02-04       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.